Intervention

Neratinib + endocrine therapy

ClinicalTrials.gov intervention label

Clinical trials2

Recruiting0

Common conditions4

Lead sponsors shown2

Clinical trials

2 shown

Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast CancerNCT07729046 · 2027-07-01

NOT_YET_RECRUITING

Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast CancerNCT04460430 · 2020-07-23

Common conditions

Breast Cancer1 ER+, HER2-, Metastatic Breast Cancer1 Metastatic Invasive Breast Cancer1 Resistant Breast Cancer1

Leading sponsors

SOLTI Breast Cancer Research Group1 University of California, San Diego1

Trial status mix

NOT_YET_RECRUITING1

TERMINATED1

Phase mix

PHASE22

How to interpret this record

CureCurrent links normalized diseases, medicines, registry study labels, sponsors and research sites. A link is not the same as a finding of clinical effectiveness. Our research guides explain how to compare studies, decode RxNorm identities, and avoid over-interpreting site and trial counts. See the published database coverage for mapping completeness.

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.